Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (XLO)

Q: What does CUSIP 98422T100 represent in this 13F holders report?

CUSIP 98422T100 is the security identifier for XLO - Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share used to aggregate holder disclosures.

Q: How many institutions held XLO - Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share in Q2 2022?

29 institutional investors reported XLO - Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share for Q2 2022. Use the holders table for investor-level position and value details.

CUSIP: 98422T100

Q2 2022 13F Holders as of 30 Jun 2022

Type / Class: Equity / Common Stock, par value $0.0001 per share
Shares outstanding: 73,644,024
Total 13F shares: 17,880,380
Share change: -894,481
Total reported value: $52,211,910
Price per share: $2.92
Number of holders: 29
Value change: -$3,647,986
Number of buys: 12
Number of sells: 27

Quarterly Holders Quick Answers

What is CUSIP 98422T100?
CUSIP 98422T100 identifies XLO - Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q3 2022
Previous quarter: Q1 2022

Recent filing periods for CUSIP 98422T100:

Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024

Top shareholders of XLO - Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
Bain Capital Life Sciences Investors, LLC	13F 3/4/5	Company · 10%+ Owner	3.8%	2,805,413	$19,834,000	—	31 Mar 2022	13F 3/4/5
Atlas Venture Life Science Advisors, LLC	13F	Company	3.7%	2,759,344	$19,509,000	—	31 Mar 2022	13F
FMR LLC	13F 3/4/5	Company · Other*	3.5%	2,590,722	$18,316,000	—	31 Mar 2022	13F 3/4/5
DEERFIELD MANAGEMENT COMPANY, L.P.	13F	Company	2.8%	2,078,692	$14,696,000	—	31 Mar 2022	13F
RA CAPITAL MANAGEMENT, L.P.	13F	Company	2.7%	2,002,217	$14,156,000	—	31 Mar 2022	13F
RiverVest Venture Management LLC	13F	Company	2%	1,441,444	$10,191,000	—	31 Mar 2022	13F
Rock Springs Capital Management LP	13F 3/4/5	Company · 10%+ Owner	1.6%	1,191,094	$8,421,000	—	31 Mar 2022	13F 3/4/5
AJU IB Investment Co., Ltd.	13F	Company	0.91%	667,742	$4,721,000	—	31 Mar 2022	13F
Soleus Capital Management, L.P.	13F	Company	0.65%	477,495	$3,376,000	—	31 Mar 2022	13F
Artal Group S.A.	13F	Company	0.61%	450,000	$3,182,000	—	31 Mar 2022	13F
VANGUARD GROUP INC	13F	Company	0.57%	416,393	$2,944,000	—	31 Mar 2022	13F
HARVARD MANAGEMENT CO INC	13F	Company	0.56%	416,059	$2,942,000	—	31 Mar 2022	13F
NORGES BANK	13F	Company	0.54%	400,000	$2,828,000	—	31 Mar 2022	13F
SV7 Impact Medicine Fund LP	3/4/5	10%+ Owner	— class O/S missing	3,227,264	$2,678,630	—	26 Oct 2021	3/4/5
BlackRock Finance, Inc.	13F	Company	0.41%	299,756	$2,119,000	—	31 Mar 2022	13F
James E. Flynn	3/4/5	Possible Member of 10% Group, 10%+ Owner	— class O/S missing	2,287,944	$1,898,994	—	26 Oct 2021	3/4/5
FIL Ltd	13F 3/4/5	Company · Other*	0.3%	218,705	$1,546,000	—	31 Mar 2022	13F 3/4/5
TAKEDA PHARMACEUTICAL CO LTD	3/4/5	10%+ Owner	— class O/S missing	1,475,121	$1,224,350	—	26 Oct 2021	3/4/5
RiverVest Venture Fund IV, L.P.	3/4/5	10%+ Owner	— class O/S missing	1,441,444	$1,196,399	—	26 Oct 2021	3/4/5
Monashee Investment Management LLC	13F	Company	0.22%	163,066	$1,153,000	—	31 Mar 2022	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	0.19%	141,710	$1,001,000	—	31 Mar 2022	13F
BAY CITY CAPITAL LLC	3/4/5	10%+ Owner	— class O/S missing	1,129,490	$937,477	—	26 Oct 2021	3/4/5
STATE STREET CORP	13F	Company	0.13%	93,861	$664,000	—	31 Mar 2022	13F
Merck KGaA	3/4/5	10%+ Owner	— class O/S missing	680,825	$565,085	—	26 Oct 2021	3/4/5
NORTHERN TRUST CORP	13F	Company	0.09%	63,573	$449,000	—	31 Mar 2022	13F
Bank of New York Mellon Corp	13F	Company	0.03%	21,029	$149,000	—	31 Mar 2022	13F
Alexandria Venture Investments, LLC	3/4/5	10%+ Owner	— class O/S missing	166,423	$138,131	—	26 Oct 2021	3/4/5
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	13F	Company	0.02%	16,100	$114,000	—	31 Mar 2022	13F
Simon M. Tomlinson	3/4/5	10%+ Owner	— class O/S missing	131,117	$108,827	—	21 Oct 2021	3/4/5
John Charles Williams	3/4/5	10%+ Owner	— class O/S missing	100,080	$83,066	—	21 Oct 2021	3/4/5
Of Ulrich Rodeck Estate	3/4/5	10%+ Owner	— class O/S missing	100,080	$83,066	—	21 Oct 2021	3/4/5
Nuveen Asset Management, LLC	13F	Company	0.02%	11,284	$80,000	—	31 Mar 2022	13F
Timothy P. Clackson	3/4/5	10%+ Owner	— class O/S missing	90,956	$75,493	—	21 Oct 2021	3/4/5
Granite Point Capital Management, L.P.	13F	Company	0.01%	10,000	$71,000	—	31 Mar 2022	13F
NEW YORK STATE COMMON RETIREMENT FUND	13F	Company	0.01%	5,632	$40,000	—	31 Mar 2022	13F
JPMORGAN CHASE & CO	13F	Company	0.01%	4,844	$34,000	—	31 Mar 2022	13F
Tower Research Capital LLC (TRC)	13F	Company	0.01%	4,294	$30,000	—	31 Mar 2022	13F
DEUTSCHE BANK AG\	13F	Company	0.01%	4,026	$28,000	—	31 Mar 2022	13F
AMERICAN INTERNATIONAL GROUP, INC.	13F	Company	0.01%	3,795	$27,000	—	31 Mar 2022	13F
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	13F	Company	0%	3,208	$23,000	—	31 Mar 2022	13F
BANK OF AMERICA CORP /DE/	13F	Company	0%	2,611	$19,000	—	31 Mar 2022	13F
MORGAN STANLEY	13F	Company	0%	2,040	$14,000	—	31 Mar 2022	13F
STRS OHIO	13F	Company	0%	1,700	$12,000	—	31 Mar 2022	13F
WELLS FARGO & COMPANY/MN	13F	Company	0%	1,663	$12,000	—	31 Mar 2022	13F
BARCLAYS PLC	13F	Company	0%	1,243	$8,000	—	31 Mar 2022	13F
AMALGAMATED BANK	13F	Company	0%	1,078	$8,000	—	31 Mar 2022	13F
Amalgamated Financial Corp.	13F	Company	0%	1,078	$8,000	—	31 Mar 2022	13F
Rachel Humphrey	3/4/5	Director	— class O/S missing	9,444	$7,839	—	21 Oct 2021	3/4/5
UBS Group AG	13F	Company	0%	964	$7,000	—	31 Mar 2022	13F
Legal & General Group Plc	13F	Company	0%	698	$5,000	—	31 Mar 2022	13F

Institutional Holders of Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (XLO) as of Q2 2022

As of 30 Jun 2022, Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (XLO) was held by 29 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 17,880,380 shares. The largest 10 holders included Bain Capital Life Sciences Investors, LLC, Atlas Venture Life Science Advisors, LLC, FMR LLC, DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), RA CAPITAL MANAGEMENT, L.P., RiverVest Venture Management LLC, Rock Springs Capital Management LP, AJU IB Investment Co., Ltd., Soleus Capital Management, L.P., and Artal Group S.A.. This page lists 29 institutional shareholders reporting positions in this security for the Q2 2022 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q2 2022 vs Q1 2022 Across Filers

Q1 2022 holders

Q2 2022 holders

Holder diff

-12

Investor	Q1 2022 Shares	Q2 2022 Shares	Share Diff	Share Chg %	Q1 2022 Value $	Q2 2022 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.